Home > Resources > Whitepapers > Cell Therapy Today - New Developments in Immunotherapy

Cell Therapy Today - New Developments in Immunotherapy

December 6, 2018

PHCbi brand Cell-IQ™ CO2 and O2 incubators are designed to deliver reproducibility critical to immunotherapy and regenerative medicine from one day to the next. Your desired temperature and gas concentrations replicate the in vivo model of any cell culture environment with precision and predictability. Our SafeCell™ and inCu saFe® technologies protect your work in vitro.

Spotlight

SHJ Hospital Pipelines Limited

Formed in 1967 to supply medical pipelines to NHS hospitals in London and the South East of England, SHJ Hospital Pipelines Ltd has grown into one of the most respected companies supplying to the NHS. Health estates have benefited from our expertise and many Estates Managers have recognised our commitment to quality. Products we have currently, EVOLUTION – for remotely monitored medical gas alarms, and EMPOWER– an intelligent medical gas plant control system under Products.

OTHER WHITEPAPERS

Scalable Rubella production in scale-X™ bioreactor with MRC-5 cells

whitePaper | November 18, 2022

Due to vaccine delivery gap for Rubella disease, global immunization is still limited in some parts of the world. In this paper we will demonstrate how one scale-X™ carbo fixed-bed bioreactor system.

Impurity profiling and analysis of TheraPure GMP nucleotides

whitePaper | March 22, 2023

Nucleoside triphosphates (NTPs) are key building blocks of many nucleic acid therapeutics and vaccines. These molecules are a vital component of revolutionary new medicines.

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Establishment of the basidiomycete Fomes fomentarius for the production of composite materials

whitePaper | February 24, 2022

Filamentous fungi of the phylum Basidiomycota are considered as an attractive source for the biotech‑ nological production of composite materials. The ability of many basidiomycetes to accept residual lignocellulosic plant biomass from agriculture and forestry.

Vaccine and Biologics Development in an Emerging Post Pandemic Landscape

whitePaper | September 20, 2022

It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.